1. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
- Author
-
Dieleman, E., Woude, L. van der, Os, R. van, Bockel, L. van, Coremans, I., Es, C. van, Jaeger, K. de, Knol, H.P., Kolff, W., Koppe, F., Pomp, J., Reymen, B., Schinagl, D., Spoelstra, F., Tissing-Tan, C., Voort van Zyp, N. van der, Wel, A. van der, Wijsman, R., Dielwart, M., Wiegman, E., Damhuis, R., Belderbos, J., Dieleman, E., Woude, L. van der, Os, R. van, Bockel, L. van, Coremans, I., Es, C. van, Jaeger, K. de, Knol, H.P., Kolff, W., Koppe, F., Pomp, J., Reymen, B., Schinagl, D., Spoelstra, F., Tissing-Tan, C., Voort van Zyp, N. van der, Wel, A. van der, Wijsman, R., Dielwart, M., Wiegman, E., Damhuis, R., and Belderbos, J.
- Abstract
Item does not contain fulltext, INTRODUCTION: Chemoradiotherapy (CRT) is the standard of care in inoperable non-small-cell lung cancer (NSCLC) patients, favoring concurrent (cCRT) over sequential CRT (seqCRT), with adjuvant immunotherapy in responders. Elderly and frail NSCLC patients have generally been excluded from trials in the past. In elderly patients however, the higher treatment related morbidity of cCRT, may outweigh the possible lower tumor control of seqCRT. For elderly patients with locally advanced NSCLC real-world data is essential to be able to balance treatment toxicity and treatment outcome. The aim of this study is to analyze acute toxicity and 3-month mortality of curative chemoradiation (CRT) in patients with stage III NSCLC and to analyze whether cCRT for elderly stage III NSCLC patients is safe. METHODS: The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R) is a national lung cancer audit that started in 2013 for patients treated with curative intent radiotherapy. All Dutch patients treated for stage III NSCLC between 2015 and 2018 with seqCRT or cCRT for (primary or recurrent) stage III lung cancer are included in this population-based study. Information was collected on patient, tumor- and treatment characteristics and the incidence and severity of acute non-hematological toxicity (CTCAE-4 version 4.03) and mortality within 3 months after the end of radiotherapy. To evaluate the association between prognostic factors and outcome (acute toxicity and mortality within 3 months), an univariable and multivariable analysis was performed. The definition of cCRT was:radiotherapy started within 30 days after the start of chemotherapy. RESULTS: Out of all 20 Dutch departments of radiation oncology, 19 centers participated in the registry. A total of 2942 NSCLC stage III patients were treated with CRT. Of these 67.2% (n = 1977) were treated with cCRT (median age 66 years) and 32.8% (n = 965) were treated with seqCRT (median age 69 years). Good performance status (WHO 0-1) was scored in 88
- Published
- 2023